pH-D Feminine Health Advances Women's Health with New Trial
pH-D Feminine Health Breaks New Ground in Women's Health
pH-D Feminine Health proudly announces the launch of its first randomized, placebo-controlled, double-blinded Phase 3 clinical trial designed to evaluate the efficacy of boric acid suppositories. This significant milestone comes with the clearance from the U.S. Food and Drug Administration (FDA), aiming to establish boric acid as a viable treatment option for yeast infections and ultimately support a New Drug Application (NDA).
Importance of the Phase 3 Clinical Trial
This pivotal study represents a crucial step towards better understanding the safety and effectiveness of boric acid suppositories in treating yeast infections. Deeannah Seymour, the co-founder and CEO of pH-D Feminine Health, emphasized the importance of the trial, stating, "By sponsoring this clinical research, we aspire to generate the scientific evidence that women truly deserve. Through this endeavor, we aim to make boric acid more accessible, ensuring that affordable solutions are readily available to every woman who needs them."
Expert Insights on Boric Acid Efficacy
In accordance with clinical guidelines established by the American College of Obstetricians and Gynecologists, boric acid is recognized as a second-line treatment option for managing vaginitis among non-pregnant women. Moreover, the Centers for Disease Control and Prevention endorses the efficacy of boric acid in handling recurrent Vulvovaginal candidiasis (VVC), noting that a dosage of 600 mg administered vaginally can lead to positive health outcomes.
Addressing a Gap in Women's Healthcare
Dr. Aparna D. Shah, an OB/GYN and urogynecology specialist, highlighted how this trial is bridging a long-existing gap in clinical evidence regarding boric acid. "The rigorous structure of this study emphasizes the local treatment of vaginal yeast infections, and we anticipate that these findings will contribute significantly to the therapeutic applications of boric acid in women's health," said Dr. Shah.
Current Status of the Clinical Trial
Currently, enrollment for the Phase 3 study is underway across nearly 20 trial sites nationwide. Anticipated completion of the study is set for June 2026. This level of commitment reflects pH-D's dedication to advancing women's health through scientific research and clinical validation.
About pH-D Feminine Health
Since its inception in 2014, pH-D Feminine Health has taken innovative strides in developing boric acid suppository products. While the pH-D boric acid vaginal suppository is still in investigational stages and not yet approved by the FDA, the company continues to promote its retail products both online and across the nation. As a recognition of her impactful contributions, Deeannah Seymour has been acknowledged as a Forbes 50 Over 50: Innovation 2025 member and an INC. 5000 recipient.
Connecting with pH-D Feminine Health
For more insights or inquiries about their pioneering work, interested parties are encouraged to reach out. pH-D Feminine Health remains focused on enhancing women's health through innovative research and product development.
Frequently Asked Questions
What is the purpose of the Phase 3 clinical trial?
The Phase 3 clinical trial aims to evaluate the safety and efficacy of boric acid suppositories in treating yeast infections.
Who is leading the clinical trial?
The trial is sponsored by pH-D Feminine Health, with support from healthcare professionals specializing in women's health.
What are boric acid suppositories used for?
Boric acid suppositories are being evaluated as a potential treatment option for yeast infections, particularly in non-pregnant women.
When is the trial expected to finish?
Enrollment for the trial has begun, and it is projected to conclude in June 2026.
How can I learn more about pH-D products?
Visit the pH-D Feminine Health website to explore their full range of feminine health products and updates on ongoing clinical research.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
